Belotecan Hydrochloride

盐酸贝洛替康

Report date: 2022/05/18 17:41:56
NME

Base Information

Drug NameBelotecan Hydrochloride
Drug Alias Name贝洛替康BelotecanumCamtobellEQ-917CKD-602 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsNeoplasms
Global Approved IndicationsCarcinoma, Non-Small-Cell LungOvarian Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2003/12/10
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesChong Kun Dang Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesChong Kun Dang Pharmaceutical Corp
Inactive CompaniesUniversity Of Pittsburgh
Active IndicationsCarcinoma, Non-Small-Cell LungOvarian Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01CE04
Related LinksWikipediaKEGG